NuCana PLC (NCNA) - Total Assets
Based on the latest financial reports, NuCana PLC (NCNA) holds total assets worth $32.31 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NuCana PLC shareholders equity for net asset value and shareholders' equity analysis.
NuCana PLC - Total Assets Trend (2014–2024)
This chart illustrates how NuCana PLC's total assets have evolved over time, based on quarterly financial data.
NuCana PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
NuCana PLC's total assets of $32.31 Million consist of 83.0% current assets and 17.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.7% |
| Accounts Receivable | $4.64 Million | 31.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.20 Million | 14.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how NuCana PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NuCana PLC (NCNA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NuCana PLC's current assets represent 83.0% of total assets in 2024, a decrease from 98.4% in 2014.
- Cash Position: Cash and equivalents constituted 45.7% of total assets in 2024, down from 94.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 31.4% of total assets.
NuCana PLC Competitors by Total Assets
Key competitors of NuCana PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
NuCana PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.76 | 1.12 | 12.49 |
| Quick Ratio | 4.76 | 1.12 | 12.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $23.57 Million | $1.86 Million | $93.66 Million |
NuCana PLC - Advanced Valuation Insights
This section examines the relationship between NuCana PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.23 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -46.9% |
| Total Assets | $14.77 Million |
| Market Capitalization | $3.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values NuCana PLC's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: NuCana PLC's assets decreased by 46.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NuCana PLC (2014–2024)
The table below shows the annual total assets of NuCana PLC from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $14.77 Million | -46.88% |
| 2023-12-31 | $27.81 Million | -52.26% |
| 2022-12-31 | $58.25 Million | -24.81% |
| 2021-12-31 | $77.47 Million | -28.13% |
| 2020-12-31 | $107.79 Million | +53.40% |
| 2019-12-31 | $70.27 Million | -19.40% |
| 2018-12-31 | $87.19 Million | -9.52% |
| 2017-12-31 | $96.36 Million | +254.06% |
| 2016-12-31 | $27.21 Million | -14.11% |
| 2015-12-31 | $31.68 Million | +88715.70% |
| 2014-12-31 | $35.67K | -- |
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline in… Read more